Reovirus for the treatment of neoplasia

Details Reovirus for the treatment of neoplasia Reovirus for the treatment of neoplasia

1997-08-13

2000-08-29

McKelvey, Terry

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Virus or bacteriophage

A61K 3576

Patent

active

061104612

ABSTRACT:
Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

REFERENCES:
patent: 4108983 (1978-08-01), Wallack
G. Hashiro et al., "The Preferential Cytotoxicity of Reovirus for certain transformed cell lines", Archives of Virology 54(4):307-315 (1977).
J.E. Strong et al., "The Molecular Basis of Viral Oncolysis: Usurption of the Ras signaling Pathway by Reovirus", The EMOB Journal 17(12):3351-3362 (Jun. 15, 1998).
Tang et al., "Short communications: Recognition of the Epidermal Growth Factor Receptor by Reovirus" Virology 197:412-414 (1993).
Sharp et al., "Homologous regions of the .alpha. subunit of eukaryotic translational initiation factor 2 (eIF2.alpha.) and the vaccinia virus K3L gene product interact with the same domain within the dsRNA-activated protein kinase (PKR)" Eur. J. Biochem. 250:85-91 (1997).
Randazzo et al., "Herpes Simplex virus 1716, and ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40" J. of Gen. Virol. 78:3333-3339 (1997).
He et al., "Suppression of the phenotype of .gamma..sub.1 34.5-herpes simplex virus 1: Failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the .alpha.47 Gene" J. of Virol. 71(8):6049-6054 (Aug. 1997).
Gale, Jr. et al., "Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein" Virology 230:217-227 (1997).
Kawagishi-Kobayashi et al., "Regulation of the protein kinase PKR by the vaccinia viurs pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the pKR substrate 3IF2.alpha." Mol. and Cell Biol. 17(7):4146-4158 (1997).
Steele, T.A. and Cox, D.C., "Reovirus Type 3 Chemoimmunotherapy of Murine Lymphoma is Abrogated by Cyclosporine," Cancer Biotherapy, 10(4): 307-315 (1995).
Cahill, M.A., et al., "Signalling pathways: Jack of all cascades," Current Biology, 6(1) :16-19 (1996).
Macara, I.G., et al, "The Ras superfamily of GTPases," The FASEB Journal, 10:625-630 (1996).
Marshall, C.J., "Ras effectors," Current Opinion in Cell Biology, 8:197-204 (1996).
Strong, J.E. and Lee, P.W.K., "The v-erB Oncogene Confers Enhanced Cellular Susceptibility to Reovirus Infection," J. of Virol. 70(1) :612-616 (1996).
Strong, J.E. et al., "Evidence That the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency," Virol. 197:405-411.
Duncan, M.R. et al., "Differential Sensitivity of Normal and Transformed Human Cells to Reovirus Infection," J. of Virol. 28(2) :444-449 (1978).
Soroceanu, L. et al., "The Use of Genetically Engineered HSV-1 Viruses in Treatment of Malignant Intracerebral Gliomas," FASEB.J. 9(3): Abstract 812 p. A139 (1995).
Andreansky, S.S. et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).
Boviatsis, E.J. et al., "Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase," Gene Therapy 1:323-331 (1994).
Taterka, J. et al., "Characterization of Cytotoxic Cells from Reovirus-Infected SCID Mice: Activated Cells Express Natural Killer-and Lymphokine-Activated Killer-Like Activity but Fail To Clear Infection," J. of Virol. 69 (6) :3910-3914 (1995).
Zhang, J.F. et al., " Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to virual oncolysis and gene therapy," Proc. Natl. Acad. Sci. USA 93:4513-4518 (1996).
Chambers, R. et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma," Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995).
Williams, M.E. et al., "Rejection of reovirus-treated L1210 leukemia cells by mice," Cancer Immunol. Immunother. 23:87-92 (1986).
Theiss, J.C. et al., "Effect of Reovirus Infection on Pulmonary Tumor Response to Urethan in Strain A Mice," J. Natl Cancer Inst 61:131-134 (1978).
Kollmorgen, G.M. et al., "Immunotherapy of EL4 Lymphoma with Reovirus," Cancer Immunol. Immunother. 1:239-244 (1976).
Bryson, J.S. and Cox, D.C., "Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia," Cancer Immunol. Immunother. 26: 132-138 (1988).
Gentsch, J.R. and Pacitti, A.F., "Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3 Reovirus Attachment to Murine L Cells," J. of Virol. 56 (2) :356-364 (1985).
Armstrong, G.D. et al., "Studies on Reovirus Receptors of L Cells: Virus Binding Characteristics and Comparison with Reovirus Receptors of Erythrocytes," Virology 138:37-48 (1984).
Samuel, C.E. and Brody, M.S., "Biosynthesis of Reovirus-Specified Polypeptides--2-Aminopurine Increases the Efficiency of Translation of Reovirus s1 mRNA but not 54 mRNA in Transfected Cells," Virology 176:106-113 (1990).
Mundschau, L.J. and Faller, D.V., "Oncogenic ras Induces an Inhibitor of Double-stranded RNA-dependent Eukaryotic Initiation Factor 2.alpha.-kinase Activation," The J. of Biol. Chem. 267 (32):23092-23098 (1992).
Avruch, J. et al., "Raf meets Ras: completing the framework of a signal transduction pathway," Trends Bioch. Sci. 19:279 (1994).
Strong, J.E. et al., "Evidence That the Epidermal Growth Factor Receptor on Host Cells confers Reovirus Infection Efficiency," Virology 197, 405-411 (1993).
Barbacid, M., "ras Genes," Annu. Rev. Biochem. 56:779-827 (1987).
Hershey, J.W.B., "Translation Control in Mammalian Cells," Annu. Rev. Biochem. 60:717-755 (1991).

Affiliated with

Also associated with

Rating

Reovirus for the treatment of neoplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reovirus for the treatment of neoplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of neoplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1246691